Effectiveness and safety of the pre-prescription of garenoxacin in comparison to moxifloxacin for low-risk febrile neutropenia in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy
- 39 Downloads
The purpose of this study was to compare the efficacy of the pre-prescription of garenoxacin mesylate hydrate (GRNX) with that of moxifloxacin hydrochloride (MFLX) in the management of breast cancer patients with low-risk febrile neutropenia.
Data from female patients who had been instructed to take previously prescribed oral GRNX or MFLX for 3 days during adjuvant and neoadjuvant chemotherapy if their body temperature exceeded 38 °C were analyzed. This study compared the effectiveness between these fluoroquinolones using a propensity score matching analysis.
The 330 patients received 1192 administrations of chemotherapy between May 2007 and April 2014 and 136 (41.2%) patients had a total of 212 (17.8%) febrile episodes. The frequencies of febrile episodes were 19.5% (113/579) and 16.2% (99/613) in the GRNX and MFLX groups, respectively. After propensity score matching, 384 episodes were matched in each group. Febrile events occurred in 80 and 56 cases in the GRNX and MFLX groups, respectively. Treatment success was identified in 80.0% (64/80) of cases in the GRNX group and 64.3% (36/56) of cases in the MFLX group (P = 0.0494). Additionally, the therapeutic use of granulocyte-colony stimulating factor was 6.3% (5/80) of cases in the GRNX group and 17.9% (10/56) of cases in the MFLX group (P = 0.0498). There were few differences in the frequency of adverse effects between the two groups.
These results indicate that the pre-prescription of GRNX may be a more effective option for the management of low-risk febrile neutropenia during adjuvant and neoadjuvant chemotherapy for breast cancer.
KeywordsPre-prescription Garenoxacin Moxifloxacin Low-risk febrile neutropenia Breast cancer Adjuvant chemotherapy
Abbreviations in Figures and Tables
garenoxacin mesylate hydrate
body surface area
body mass index
5-fluorouracil, epirubicin, cyclophosphamide
granulocyte-colony stimulating factor
We would like to thank Editage (www.editage.jp) for English language editing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
Research involving human participants and/or animals
This study was approved by the Human Subjects Review Committee at Osaka City University (No. 3725).
For this type of study, formal consent is not required.
- 1.Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93. https://doi.org/10.1093/cid/cir073 CrossRefPubMedGoogle Scholar
- 2.National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology prevention and treatment of cancer-related infections version 1.2018. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf. Accessed 3 May 2018
- 3.Kimura K, Tanaka S, Iwamoto M, Fujioka H, Sato N, Terasawa R, Kawaguchi K, Matsuda J, Umezaki N, Uchiyama K (2016) Outpatient management without initial assessment for febrile patients undergoing adjuvant chemotherapy for breast cancer. Mol Clin Oncol 5:385–390. https://doi.org/10.3892/mco.2016.992 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Kern WV, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, de Bock R, Paesmans M, Viscoli C, Calandra T (2013) Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy—EORTC infectious. J Clin Oncol 31:1149–1156. https://doi.org/10.1200/JCO.2012.45.8109 CrossRefPubMedGoogle Scholar
- 6.Takahashi M, Takahashi K, Ogawa K, Takashima T, Mitsukawa Y, Kashiwagi S, Noda S, Onoda N, Ohira M, Nagayama K (2017) Effectiveness evaluation of pre-prescription of moxifloxacin hydrochloride in febrile neutropenia during adjuvant or neoadjuvant chemotherapy for breast cancer. Jpn J Pharm Heal Care Sci (in Japanese) 43:577–584CrossRefGoogle Scholar
- 7.European Medicines Agency (2008) Questions and answers on the recommendation to restrict the use of oral formulations of moxifloxacin-containing medicines. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/moxifloxacin_107/WC500011982.pdf. Accessed 3 May 2018
- 8.Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 20:3114–3121. https://doi.org/10.1200/JCO.2002.11.005 CrossRefPubMedGoogle Scholar
- 9.Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y, for Japan Breast Cancer Research Group (JBCRG) (2008) Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110:531–539. https://doi.org/10.1007/s10549-007-9744-z CrossRefPubMedGoogle Scholar
- 10.Fung-Tomc JC, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, Washo T, Gradelski E, Valera L, Bonner DP (2000) Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother 44:3351–3356. https://doi.org/10.1128/AAC.44.12.3351-3356.2000 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, Devaux Y, Lancry L, Chvetzoff G, Bachelot T, Chelghoum M, Biron P (2008) Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 16:1017–1023. https://doi.org/10.1007/s00520-007-0383-z CrossRefPubMedGoogle Scholar
- 18.Noreddin AM, Reese AA, Ostroski M et al (2007) Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. Clin Ther 29:2685–2689. https://doi.org/10.1016/j.clinthera.2007.12.019 CrossRefPubMedGoogle Scholar
- 19.Schaumann R, Janssen E, Funke M, Stingu CS, Genzel GH, Janssen M, Rodloff AC (2013) In vitro activities of levofloxacin, gatifloxacin, moxifloxacin and garenoxacin against Bacteroides fragilis strains evaluated by kill kinetics. J Med Microbiol 62:576–581. https://doi.org/10.1099/jmm.0.053280-0 CrossRefPubMedGoogle Scholar
- 21.Pukar M, Hajare A, Krishnaprasad K, Bhargava A (2015) Post-approval , observational study with garenoxacin a newer des-fluoroquinolone in uncomplicated urinary tract infections in Vadodara , India. 1:2–5. https://doi.org/10.17354/SUR/2015/02
- 24.Kim CG, Sohn J, Chon H, Kim JH, Heo SJ, Cho H, Kim IJ, Kim SI, Park S, Park HS, Kim GM (2016) Incidence of febrile neutropenia in Korean female breast cancer patients receiving preoperative or postoperative doxorubicin/cyclophosphamide followed by docetaxel chemotherapy. J Breast Cancer 19:76–82. https://doi.org/10.4048/jbc.2016.19.1.76 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Takabatake D, Taira N, Hara F, Sien T, Kiyoto S, Takashima S, Aogi K, Ohsumi S, Doihara H, Takashima S (2009) Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. Jpn J Clin Oncol 39:478–483. https://doi.org/10.1093/jjco/hyp050 CrossRefPubMedGoogle Scholar
- 26.Ishii N, Fujimori T, Kasagawa T, Udagawa I (2016) Analysis of the risk factors of febrile neutropenia among 72 women receiving FEC in early breast cancer chemotherapy. Gan To Kagaku Ryoho 43:1555–1557 (in Japanese)Google Scholar
- 28.Japanese Society of Medical Oncology (2017) Practical guideline for febrile neutropenia (FN), 2nd edn. Nankodo, Tokyo (in Japanese)Google Scholar